{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T09:31:33Z","timestamp":1780479093910,"version":"3.54.1"},"reference-count":18,"publisher":"Cambridge University Press (CUP)","issue":"8","license":[{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["Infect. Control Hosp. Epidemiol."],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec id=\"S0899823X22002392_as1\"><jats:title>Objective:<\/jats:title><jats:p>To determine whether discontinuing active screening for vancomycin-resistant <jats:italic>Enterococcus<\/jats:italic> (VRE) in Alberta, Canada, acute-care facilities had an associated impact on the rate of rise of hospital-acquired (HA) VRE bloodstream infection (VRE-BSI).<\/jats:p><\/jats:sec><jats:sec id=\"S0899823X22002392_as2\"><jats:title>Setting:<\/jats:title><jats:p>Acute-care facilities in Alberta, Canada.<\/jats:p><\/jats:sec><jats:sec id=\"S0899823X22002392_as3\"><jats:title>Patients:<\/jats:title><jats:p>All patients who were admitted to Alberta Health Services or Covenant Health acute-care facilities between January 1, 2013, and March 31, 2020, and who met the definition for hospital-acquired VRE-BSI were included in the analyses.<\/jats:p><\/jats:sec><jats:sec id=\"S0899823X22002392_as4\"><jats:title>Methods:<\/jats:title><jats:p>An intervention time-series Poisson regression was used to determine the slope change in VRE incidence between the pre- and postintervention (screening) periods. The patient population was separated into 3 cohorts: group 1 (low risk, VRE screening stopped), group 2 (high risk, VRE screening stopped), and group 3 (high risk, VRE screening continued). For all groups, a level- and slope-change model was used.<\/jats:p><\/jats:sec><jats:sec id=\"S0899823X22002392_as5\"><jats:title>Results:<\/jats:title><jats:p>We did not find a statistically significant difference in the slope change or rate of rise in VRE-BSI before and after the intervention, with incidence rate ratio (IRRs) of 1.015 (95% confidence interval [CI], 0.982\u20131.049), 1.025 (95% CI, 0.967\u20131.086), and 0.989 (95% CI, 0.924\u20131.059) for groups 1, 2 and 3, respectively.<\/jats:p><\/jats:sec><jats:sec id=\"S0899823X22002392_as6\"><jats:title>Conclusions:<\/jats:title><jats:p>In Alberta, the rate of HA VRE-BSI has remained consistent, and our findings indicate that there has been no increase in the rate of rise of HA VRE-BSI in sites or units that discontinued screening for VRE, regardless of patient risk group.<\/jats:p><\/jats:sec>","DOI":"10.1017\/ice.2022.239","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T12:18:09Z","timestamp":1665058689000},"page":"1289-1293","update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":3,"title":["The associated impact of standardized admission screening on vancomycin-resistant <i>Enterococci<\/i> bloodstream infections"],"prefix":"10.1017","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4282-9410","authenticated-orcid":false,"given":"Ted R.","family":"Pfister","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanda","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0413-6218","authenticated-orcid":false,"given":"Ye","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6278-9519","authenticated-orcid":false,"given":"Jennifer","family":"Ellison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Bush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2022,10,6]]},"reference":[{"key":"S0899823X22002392_ref4","doi-asserted-by":"publisher","DOI":"10.1086\/510629"},{"key":"S0899823X22002392_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2017.08.031"},{"key":"S0899823X22002392_ref12","unstructured":"12. Canadian Consensus Development Conference: surveillance and screening of AROs (antimicrobial-resistant organisms)\u2014consensus statement of the jury. IHE Consensus Statements, volume 6. Edmonton Institute of Health Economics website. http:\/\/www.ihe.ca\/download\/consensus_statement_on_ surveillance_screening_for_aros_antimicrobial_resistant_organisms.pdf. Published 2014. Accessed March 24, 2017."},{"key":"S0899823X22002392_ref17","doi-asserted-by":"publisher","DOI":"10.1086\/502411"},{"key":"S0899823X22002392_ref9","unstructured":"9. CHICA\u2013Canada position statement\u2013VRE screening and contact precautions. Infection Prevention and Control Canada website. https:\/\/ipaccanada.org\/photos\/custom\/Members\/pdf\/VRE%20Position%20Statement%20-%20FINAL.pdf. Updated June 29, 2012. Accessed November 26, 2019."},{"key":"S0899823X22002392_ref15","doi-asserted-by":"publisher","DOI":"10.3201\/eid2609.201576"},{"key":"S0899823X22002392_ref6","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa009"},{"key":"S0899823X22002392_ref14","first-page":"348","article-title":"Interrupted time series regression for the evaluation of public health interventions: a tutorial","volume":"46","author":"Bernal","year":"2017","journal-title":"Int J Epidemiol"},{"key":"S0899823X22002392_ref3","volume-title":"Routine Practices and Additional Precautions in All Health Care Settings","year":"2013"},{"key":"S0899823X22002392_ref18","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis765"},{"key":"S0899823X22002392_ref2","unstructured":"2. Vancomycin-resistant Enterococci Infections in Canadian Acute-Care Hospitals: Surveillance Report January 1, 1999 to December 31, 2011. Ottawa: Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada; 2013."},{"key":"S0899823X22002392_ref16","doi-asserted-by":"publisher","DOI":"10.1086\/377733"},{"key":"S0899823X22002392_ref8","unstructured":"8. Nadolny, E , Prematunge, C , Policarpio, M , et al. Vancomycin-resistant Enterococcus (VRE) screening and isolation practices (SIP) scan: hospital-based infection control policy in Ontario (2012\u20132015). Proceedings of Wisdom Begins with Wonder: IPAC Canada 2016 Annual Conference; May 15\u201317, 2016; Niagara Falls (ON). Winnipeg: Infection Prevention and Control Canada."},{"key":"S0899823X22002392_ref5","doi-asserted-by":"publisher","DOI":"10.9778\/cmajo.20160121"},{"key":"S0899823X22002392_ref7","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2016.235"},{"key":"S0899823X22002392_ref1","doi-asserted-by":"publisher","DOI":"10.14745\/ccdr.v40is2a02"},{"key":"S0899823X22002392_ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2015.06.003"},{"key":"S0899823X22002392_ref13","unstructured":"13. Bloodstream infection (BSI) provincial surveillance protocol\u20132020. Alberta Health Services Infection Prevention & Control Protocol website. https:\/\/www.albertahealthservices.ca\/assets\/healthinfo\/ipc\/hi-ipc-sr-cdi-protocol.pdf. Accessed January 2021."}],"container-title":["Infection Control &amp; Hospital Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0899823X22002392","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T08:31:33Z","timestamp":1692952293000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0899823X22002392\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,6]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0899823X22002392"],"URL":"https:\/\/doi.org\/10.1017\/ice.2022.239","relation":{},"ISSN":["0899-823X","1559-6834"],"issn-type":[{"value":"0899-823X","type":"print"},{"value":"1559-6834","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,6]]},"assertion":[{"value":"\u00a9 The Author(s), 2022. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}}]}}